Reduced Disease-Free Survival Associated with Anaplastic Lymphoma Kinase Translocation (ALK plus ) in Lung Adenocarcinoma Patients with No Cigarette Smoking History

被引：0
|
作者：
Yang, Ping [1 ]
Oliveira, Andre [2 ]
Wampfler, Jason [1 ]
Boland, Jennifer M. [2 ]
Stoddard, Shawn M. [1 ]
Ericison-Johnson, Michele R. [2 ]
Tang, Hui [1 ]
Kulig, Kimary [1 ]
Yi, Eunhee S. [2 ]
机构：
[1] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S384 / S384
页数：1
相关论文
共 50 条
  • [41] Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: A case report
    Falk, Alexander T.
    Poudenx, Michel
    Otto, Josiane
    Ghalloussi, Hannah
    Barriere, Jerome
    [J]. LUNG CANCER, 2012, 78 (03) : 282 - 284
  • [42] COST-EFFECTIVENESS OF CERITINIB IN PREVIOUSLY TREATED PATIENTS WITH CRIZOTINIB IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER IN CANADA
    Zhou, Z.
    Hurry, M.
    Zhang, J.
    Fan, L.
    Zhang, C.
    Xie, J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A462 - A462
  • [43] IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities
    Charkowick, Shaun V.
    Huda, Taha I.
    Patel, Dhruv N.
    Yeagley, Michelle
    Arturo, Juan F.
    Cios, Konrad J.
    Gozlan, Etienne C.
    Chobrutskiy, Andrea
    Chobrutskiy, Boris I.
    Blanck, George
    [J]. BIOCHEMICAL GENETICS, 2024, 62 (01) : 530 - 546
  • [44] Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK) plus non-small cell lung cancer: interim analysis results of a post-marketing surveillance study
    Kaneda, Hiroyasu
    Kizaki, Minako
    Ochi, Masami
    Shiraiwa, Naoko
    Akatsu, Shigemi
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [45] Copy Number Variations in Receptor Tyrosine Kinase Signaling Cluster Stomach Adenocarcinoma Patients Into Groups With Significant Differences in Disease-Free and Overall Survival
    Vasudevan, H.
    Rhome, R.
    Buckstein, M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E572 - E572
  • [46] Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK plus NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis
    Itchins, Malinda
    Hayes, Sarah A.
    Gill, Anthony J.
    Cooper, Wendy
    O'Connell, Rachel
    Howell, Viive M.
    Clarke, Stephen J.
    Pavlakis, Nick
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (05) : e275 - e282
  • [47] Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients
    Song, Joon Seon
    Kim, Yong Seok
    Kim, Dong Kwan
    Park, Sung Il
    Jang, Se Jin
    [J]. PATHOLOGY INTERNATIONAL, 2012, 62 (03) : 182 - 190
  • [48] Low expression of Bax in non-small cell lung cancer: Predictor of poor disease-free survival in adenocarcinoma patients with surgical resection
    Lim, Ho-Yeong
    Choi, Jin-Hyuk
    Kang, Seog Yun
    Jung, Youn Mu
    Kim, Hugh Chul
    Oh, Young Taek
    Choi, Ho
    Hwang, Seong Chul
    Park, Kwang Joo
    Han, Jae Ho
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [49] Treatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK plus ) advanced non-small cell lung cancer (NSCLC) in US clinical practice
    Krebs, M. G.
    Polito, L.
    Smoljanovic, V.
    Trinh, H.
    Crane, G.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [50] BRIGATINIB AS A LEADING OPTION TO MANAGE PREVIOUSLY NOT TREATED PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) IN PORTUGAL
    Monteiro, S.
    Labisa, P.
    Fragoso, J.
    Ferreira, C.
    Cochado, S.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S90 - S90
12345